IL17A and uveitis: IL‐23/IL‐17 axis appears to be an appealing therapeutic target but, at the moment, secukinumab,79 an IL‐17 antagonist, has shown no significant effect on uveitis, whereas a phase two trial with ustekinumab, an IL‐12/IL‐23 blocker, is currently ongoing (www.clinicaltrials.gov NCT02911116).